Galectin Therapeutics Inc.
GALT
$3.98
-$0.18-4.33%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -4.68% | -5.22% | -1.35% | -5.76% | -7.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -14.24% | 8.84% | 11.45% | 1.08% | 4.11% |
| Operating Income | 14.24% | -8.84% | -11.45% | -1.08% | -4.11% |
| Income Before Tax | 8.91% | -10.14% | -14.56% | -8.09% | -11.07% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 8.91% | -10.14% | -14.56% | -8.09% | -11.07% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.91% | -10.14% | -14.56% | -8.09% | -11.07% |
| EBIT | 14.24% | -8.84% | -11.45% | -1.08% | -4.11% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 17.81% | 1.82% | -1.58% | 4.55% | -16.48% |
| Normalized Basic EPS | 10.93% | -7.00% | -10.54% | -3.66% | -7.47% |
| EPS Diluted | 17.81% | 1.82% | -1.58% | 4.55% | -16.48% |
| Normalized Diluted EPS | 10.93% | -7.00% | -10.54% | -3.66% | -7.47% |
| Average Basic Shares Outstanding | 2.40% | 3.02% | 3.57% | 4.27% | 3.32% |
| Average Diluted Shares Outstanding | 2.40% | 3.02% | 3.57% | 4.27% | 3.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |